This study was designed to investigate the relationship between adipokines in metabolic syndrome and insulin resistance. Sixty male and female subjects with or without metabolic syndrome and type 2 diabetes were included. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Compared with lean control subjects, patients with metabolic syndrome and type 2 diabetes had lower circulating levels of total adiponectin and high molecular weight (HMW) adiponectin, and higher levels of leptin and interleukin-6 (IL-6). Total and HMW adiponectin and the adiponectin/leptin (A/L) ratio were negatively correlated with HOMA-IR. After adjusting for age and sex, leptin, IL-6 and tumour necrosis factor-a (TNF-a) were positively correlated with HOMA-IR. After also adjusting for body mass index, HOMA-IR was found to be independently associated with leptin, A/L ratio and TNF-a levels. In conclusion, decreased total adiponectin and HMW adiponectin and increased leptin and IL-6 levels are characteristic of patients with metabolic syndrome and type 2 diabetes.
Introduction
Metabolic syndrome is a cluster of atherosclerotic cardiovascular disease risk factors manifested as central obesity, insulin resistance, dyslipidaemia and hypertension. 1 Central obesity appears to play an important role in metabolic syndrome and insulin resistance. Thus, the International Diabetes Federation (IDF) has suggested that central obesity is the main risk factor for metabolic syndrome. 2 Central adiposity may be linked to insulin resistance and metabolic syndrome through the production of various adipocyte-derived cytokines, known as adipokines. 3 It has been suggested that disruption of the secretion of adipokines has many metabolic consequences. 4, 5 Various adipokines, such as leptin, adiponectin, a high molecular weight (HMW) adiponectin isoform, tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) have, therefore, been studied in relation to JM Lee, SR Kim, SJ Yoo et al. Adipokines in metabolic syndrome and type 2 diabetes insulin resistance and metabolic syndrome.
Leptin is primarily produced by adipocytes and some studies show that it may also increase insulin sensitivity; 6, 7 however, other work suggests that increased leptin levels are an essential feature of human obesity and insulin resistance. 8 Adiponectin has been associated with favourable metabolic effects. For example, adiponectin levels are decreased in obese individuals with type 2 diabetes and low adiponectin levels are considered a key factor of metabolic syndrome with insulin resistance. 9 -11 Some studies, however, have demonstrated that insulin resistance and adiponectin levels are not associated, 12, 13 whereas other studies suggest that the adiponectin/leptin (A/L) ratio correlates better with insulin resistance and atherosclerosis than adiponectin or leptin alone. 14, 15 In addition, the HMW adiponectin isoform is considered to play an important role in metabolic syndrome because the ratio of HMW adiponectin to total adiponectin or levels of HMW adiponectin alone show a better correlation with insulin sensitivity than total adiponectin alone. 16 -18 Thus, the relationship of adiponectin levels with insulin resistance remains unclear. Other adipokines that have been demonstrated to be associated with metabolic syndrome and insulin resistance include the circulating inflammatory markers, TNF-α and IL-6. 19, 20 The effect of adipokines on metabolic syndrome and insulin resistance seems to stem from the influence of a combination of adipokines rather than from the effect of a single adipokine.
To the authors' knowledge, few studies have measured the various adipokines associated with insulin resistance and metabolic syndrome in the same subject, or each adipokine in relation to metabolic syndrome components and insulin resistance. The present study was designed to investigate the levels of leptin, adiponectin, HMW adiponectin, TNF-α and IL-6 in subjects with metabolic syndrome, and to evaluate the relationships between these adipokines and insulin resistance. 
Patients and methods

PATIENTS
ANTHROPOMETRIC AND BIOCHEMICAL MEASUREMENTS
Waist circumference was the minimum measurement taken between the costal margin and iliac crest. Body mass index (BMI) was calculated as weight (kg)/height squared (m 2 ). Blood pressure was measured using a standard mercury sphygmomanometer after the subject had rested for at least 10 min. All blood samples were of venous blood taken after an 8-h overnight fast. Plasma glucose and total cholesterol, triglycerides, HDL cholesterol and lowdensity lipoprotein (LDL) cholesterol levels were measured using a Hitachi 747 automatic analyser (Hitachi, Tokyo, Japan). Plasma insulin was measured using a radioimmunoassay kit (TFB Inc., Tokyo, Japan) according to the manufacturer's instruction. An estimate of insulin resistance by the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: fasting insulin (µIU/ml) × fasting glucose (mg/dl)/405.
MEASUREMENT OF SERUM ADIPOKINES
Circulating total adiponectin and serum leptin levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Linco Research, St Charles, MO, USA), HMW adiponectin concentration was determined using an ELISA kit from Alpco Diagnostics (Salem, NH, USA), and circulating TNF-α and IL-6 concentrations were determined with ELISA kits from R&D Systems (Minneapolis, MN, USA). The A/L ratio was calculated by dividing the concentration of adiponectin by that of leptin.
STATISTICAL ANALYSIS
All statistical analyses were conducted using SAS ® statistical software, version 9.1 (SAS Institute, Cary, NC, USA) for Windows ® . All continuous variables are shown as mean ± SD. Continuous variables were compared between control subjects and metabolic syndrome patients, and were adjusted for age and sex by analysis of variance. Spearman correlation analysis was used to assess the univariate associations of metabolic variables with total adiponectin, HMW adiponectin, leptin, TNF-α and IL-6. A P-value < 0.05 was to be considered statistically significant.
Results
CLINICAL CHARACTERISTICS OF PATIENTS
The study included 60 patients (29 male, 31 female) aged 40 -70 years and their clinical and metabolic parameters, adjusted for age and sex, are summarized in Table 1 . Patients with metabolic syndrome were significantly older than control subjects and there were also significant differences between the metabolic syndrome and control groups in weight, BMI, waist circumference, systolic and diastolic blood pressures, fasting blood glucose, total cholesterol, LDL cholesterol and HDL cholesterol (P < 0.05), and in insulin, triglycerides and the HOMA-IR (P < 0.001). Table 2 shows the differences in the levels of each adipokine between the two groups. Total and HMW adiponectin levels were significantly lower (P = 0.002 and P < 0.001, respectively) in patients with metabolic syndrome and type 2 diabetes compared Adipokines in metabolic syndrome and type 2 diabetes with lean control subjects, whereas leptin and IL-6 levels were significantly higher (P < 0.001 for both). There was no statistically significant difference in levels of TNF-α levels between the metabolic syndrome and control groups. Table 3 shows the correlations of each adipokine with the risk factors for metabolic syndrome in the control and metabolic syndrome groups combined after adjustment for age and sex. Total and HMW adiponectin both showed significant positive correlations with HDL cholesterol and significant negative correlations with systolic blood pressure, triglycerides, fasting blood glucose, BMI and waste circumference. Only HMW adiponectin showed a significant negative correlation with diastolic blood pressure. The A/L ratio showed significant negative correlations with all parameters, except HDL cholesterol which showed a significant positive correlation with A/L ratio. Leptin, in contrast to total and HMW adiponectin, was significantly and negatively correlated with HDL cholesterol and positively correlated with systolic blood pressure, triglycerides, fasting blood glucose, BMI and waste circumference. TNF-α showed no significant correlation with any metabolic parameter other than insulin levels. There were significant positive correlations between IL-6 and systolic and diastolic blood pressures, triglycerides, fasting blood glucose, BMI, waist circumference and insulin levels.
ADIPOKINE LEVELS
CORRELATIONS OF ADIPOKINES WITH METABOLIC SYNDROME RISK FACTORS
When the analysis was performed separately in each group, the correlations between each adipokine and the metabolic parameters differed between the groups. In the control group, adiponectin was negatively correlated with triglycerides (P < 0.05), BMI (P = 0.028) and waist circumference (P < 0.001) and positively correlated with HDL cholesterol (P < 0.05). HMW adiponectin was negatively correlated with triglycerides (P = 0.04), BMI (P = 0.02) and waist circumference (P < 0.001). Leptin was positively correlated with BMI (P < 0.001), waist circumference (P < 0.0001) and insulin (P < 0.001). TNF-α showed no significant correlation with metabolic parameters but had a significant positive correlation with insulin (P = 0.025), and IL-6 was positively correlated with diastolic blood TABLE 3: JM Lee, SR Kim, SJ Yoo et al. Adipokines in metabolic syndrome and type 2 diabetes pressure (P < 0.05), BMI (P < 0.05) and insulin (P < 0.01). In the metabolic syndrome group, adiponectin, HMW adiponectin, TNFα and IL-6 did not show any significant correlation with metabolic parameters, and only leptin was positively correlated with BMI (P = 0.018), waist circumference (P = 0.012) and insulin (P = 0.005). Table 4 shows the correlations between adipokines in the control and metabolic syndrome groups combined after adjusting for age and sex. Adiponectin and HMW adiponectin were significantly negatively correlated with IL-6 (P < 0.05 and P = 0.01, respectively). Leptin was significantly positively correlated with TNF-α (P = 0.01) and IL-6 (P = 0.03). There was no correlation between leptin and adiponectin. 
Spearman correlations (r) between adipokines and risk factors for metabolic syndrome in both groups combined (healthy lean control subjects and patients with metabolic syndrome) after adjustment for age and sex
CORRELATIONS BETWEEN ADIPOKINES
CORRELATIONS OF ADIPOKINES WITH INSULIN RESISTANCE
TABLE 4: Spearman correlations (r) between levels of total adiponectin, high molecular weight (HMW) adiponectin or leptin and levels of interleukin-6 (IL-6) and tumour necrosis factora (TNF-a) in both groups combined (healthy lean control subjects and patients with metabolic syndrome), after adjustment for age and sex
HOMA-IR
TABLE 5: Spearman correlations (r) between adipokines and the homeostasis model assessment of insulin resistance (HOMA-IR) in both groups combined (healthy lean control subjects and patients with metabolic syndrome), after adjustment for age and sex or adjustment for age, sex and body mass index (BMI)
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and HMW adiponectin were significantly and negatively correlated with HOMA-IR (P = 0.015 and P = 0.006, respectively), whereas leptin, TNF-α and IL-6 were significantly and positively correlated with it (P ≤ 0.001). The A/L ratio was also negatively correlated with HOMA-IR (P < 0.001). All these correlations remained statistically significant after adjusting for age and sex, whereas only the correlations between leptin (P = 0.01), TNF-α (P = 0.019) and the A/L ratio (P = 0.012) remained significant after adjustment for age, sex and BMI.
Discussion
It was found that circulating total adiponectin and HMW adiponectin levels in the present study were lower and leptin and IL-6 levels were higher in patients with metabolic syndrome and type 2 diabetes compared with healthy, lean individuals. To the best of the authors' knowledge, this is the first study in which total adiponectin, HMW adiponectin, leptin, IL-6 and TNF-α have all been investigated in relation to metabolic syndrome in the same patients.
As in previous studies, 11, 21, 22 total adiponectin levels in the present study were lower in patients with metabolic syndrome and type 2 diabetes. The present study also confirmed that HMW adiponectin levels were lower in patients with metabolic syndrome and type 2 diabetes. HMW adiponectin has been investigated mostly with regard to insulin sensitivity and it correlates better with glucose tolerance than total adiponectin. 18, 23, 24 Little is known, however, about the circulating levels of adiponectin in patients with metabolic syndrome compared with healthy, lean individuals.
Leptin and IL-6 levels were higher in patients with metabolic syndrome in the present study, which is consistent with previous studies showing that circulating leptin and IL-6 levels are higher in obese individuals. 25 -27 Interestingly, some investigators have reported that TNF-α levels are increased in obese people and are related to fat cell size. 28 -30 The serum TNF-α concentration was not, however, higher in patients with metabolic syndrome in the present study. This difference may be related to the characteristics of the subjects: the BMI of patients with metabolic syndrome was not higher than the BMI of control subjects in one of the previous studies. 30 Another explanation for this discrepancy is that TNFα is poorly expressed in human adipose tissue, 25, 31 and no differences in TNF-α levels between control subjects and patients with metabolic syndrome have been found. Thus, it is possible that adipose tissue is not closely related to circulating TNF-α concentrations. The TNF-α levels in patients in the present study were not correlated with BMI. Thus, obesity in patients with metabolic syndrome did not influence peripheral TNF-α concentrations.
The HMW adiponectin isoform and total adiponectin levels showed almost the same pattern of correlation with the individual components of metabolic syndrome; both were negatively correlated with systolic blood pressure, triglycerides, fasting blood glucose, BMI and waist circumference, and positively correlated with HDL cholesterol. These findings support a previous suggestion that HMW adiponectin is the most active form among the multimeric adiponectin complexes, especially in metabolic syndrome. 18, 23 In contrast to adiponectin, leptin and IL-6 showed the opposite trend with respect to correlations with individual components of metabolic syndrome; both were positively correlated with systolic blood pressure, triglycerides, fasting blood glucose, BMI, waist circumference and insulin concentration, and JM Lee, SR Kim, SJ Yoo et al. Adipokines in metabolic syndrome and type 2 diabetes negatively correlated with HDL cholesterol, although the negative correlation with HDL cholesterol was not statistically significant for IL-6. These findings confirm previous reports that leptin is related to individual metabolic syndrome components. 32 In previous reports, serum TNF-α and IL-6 were not well correlated with metabolic syndrome. 33, 34 Although this was supported by the present study showing no correlation between TNF-α and components of metabolic syndrome, IL-6 was similar to leptin in being correlated with many the components of metabolic syndrome. It is commonly accepted that IL-6 plays a key role in the assessment of insulin resistance in obese type 2 diabetic patients. 30, 35 These previous studies found that leptin and IL-6 were associated with BMI and insulin resistance, and that IL-6 and leptin were inter-related in obese type 2 diabetic patients. The data from the present study are consistent with these findings, namely that IL-6 and leptin are closely related to each other and BMI in patients with metabolic syndrome.
When the association of adipokines with insulin resistance was analysed, it was found that total adiponectin, HMW adiponectin, leptin, TNF-α, IL-6 and the A/L ratio were all correlated with HOMA-IR. These correlations were maintained after adjusting for age and sex; however, after further adjustment to include BMI, total adiponectin, HMW adiponectin and IL-6 were then not associated with HOMA-IR. Leptin and the A/L ratio were strongly correlated with the HOMA-IR after adjusting for BMI. Total adiponectin and the HMW adiponectin isoform showed a weaker relationship with the HOMA-IR than did leptin and the A/L ratio. Although many studies have reported an inverse relationship between adiponectin and insulin resistance, other studies have reported a lack of association between them. 12, 13 Thus, the relationship between adiponectin and insulin resistance is probably not one of direct cause and effect in all patients. Several clinical studies have shown that the A/L ratio is a useful parameter with which to assess insulin resistance in patients with and without diabetes. 14, 15 The A/L ratio was also shown to be a better marker of insulin resistance than either adiponectin or leptin individually in the present study, and the A/L ratio maintained a significant relationship with insulin resistance independently of BMI.
Although TNF-α levels were not increased in patients with metabolic syndrome, TNF-α correlated positively with HOMA-IR. This correlation is not associated with obesity, as mentioned previously, because TNF-α was not correlated with BMI. In fact, some studies have found that peripheral TNF-α levels are not associated with insulin resistance. 31 The findings of the present study suggested, however, that the role of TNF-α in insulin resistance may be independent of obesity or metabolic syndrome.
There were some limitations to the present study. First, the sample size was small, limiting its statistical power for detecting associations. Secondly, the cross-sectional design of the study precludes comment on causality in the relationships under study. Finally, HOMA-IR, which is not the standard method for determining insulin resistance, has limitations as a measure of insulin resistance. Nevertheless, this study represents a simultaneous investigation of specific relationships between several adipokines and the components of metabolic parameters and insulin resistance.
In conclusion, circulating total adiponectin and HMW adiponectin levels were decreased and leptin and IL-6 levels were increased in subjects with metabolic syndrome and type 2 diabetes. Each adipokine, except TNF-α, was associated with the components of metabolic syndrome. Leptin, the A/L ratio and TNF-α were associated with insulin resistance. Modulating the balance of these adipokines may be a novel therapeutic strategy in the treatment of metabolic syndrome.
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